Atticus Pharma Inc. Press Releases - EIN Presswire - Press Release Distribution Service

Published on September 23, 2026 - 12:00 GMT

Atticus Pharma Awarded $2 Million NIH Phase II SBIR Grant to Advance Cutaneous Lupus Drug Candidate

Funding supports development of ATC-001, a Z-pod®-based anandamide formulation for local delivery to cutaneous lupus lesions GREENVILLE, SC, UNITED STATES, September 23, 2026 /⁨EINPresswire.com⁩/ -- Atticus Pharma Inc., a therapeutics company developing …

Distribution channels: Healthcare & Pharmaceuticals Industry ...

Published on February 11, 2026 - 14:00 GMT

Atticus Pharma Announces Clinical Data for ATC-002, a Pharmaceutical Product Candidate for Androgenic Alopecia

GREENVILLE, SC, UNITED STATES, February 11, 2026 /⁨EINPresswire.com⁩/ -- • ATC-002 is a topical treatment designed to stimulate new hair growth in subjects with androgenic alopecia. • ATC-002 uses Atticus’s proprietary Z-pod® technology to create a …

Distribution channels: Banking, Finance & Investment Industry, Beauty & Hair Care ...

Published on June 16, 2025 - 13:00 GMT

Atticus Pharma Completes Enrollment in the First Human Clinical Trial of ATC-002 for Androgenic Alopecia

ATC-002 is an Investigational Pharmaceutical Product Candidate for Androgenic Alopecia GREENVILLE, SC, UNITED STATES, June 16, 2025 /⁨EINPresswire.com⁩/ -- • ATC-002 is a twice-daily topical treatment designed to stimulate new hair growth in subjects …

Distribution channels: Banking, Finance & Investment Industry, Beauty & Hair Care ...

Published on May 5, 2025 - 14:00 GMT

Atticus Pharma Announces Upcoming Late-Breaking Presentation of Collaborative Research at the 82nd Annual SID 2025

GREENVILLE, SC, UNITED STATES, May 5, 2025 /⁨EINPresswire.com⁩/ -- Atticus Pharma Inc, a therapeutics company focused on immunodermatology and associated conditions, today announced the presentation of pre-clinical results in a novel murine model of …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...

Published on April 14, 2025 - 15:00 GMT

Atticus Pharma Announces Initiation of the First Human Clinical Trial of ATC-002

ATC-002 is an Investigational Pharmaceutical Product Candidate for Androgenic Alopecia GREENVILLE, SC, UNITED STATES, April 14, 2025 /⁨EINPresswire.com⁩/ -- • ATC-002 is a twice-daily treatment designed to stimulate new hair growth in people with …

Distribution channels: Business & Economy, Companies ...